5:18 PM
 | 
Jul 18, 2013
 |  BC Extra  |  Clinical News

Celgene stops CLL trial in elderly patients due to deaths

Celgene Corp. (NASDAQ:CELG) discontinued the open-label Phase III ORIGIN (CLL-008) trial in 450 elderly patients with previously untreated B cell chronic lymphocytic leukemia (CLL) after an imbalance in the number of deaths was observed in patients treated with

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >